LEXINGTON, Mass. — Valo Health has appointed Chris Anagnostopoulos, Ph.D., C.Stat, as its Chief Causal AI Officer, a newly created role focused on advancing the company’s human causal biology platform for drug discovery.
In the position, Anagnostopoulos will lead efforts to translate large-scale real-world human data into causal insights that can inform the development of new therapies.
Valo is focused on improving clinical success rates by refining disease classification, identifying causal drivers earlier in the drug discovery process, and developing targeted treatments for specific patient populations. The company has access to longitudinal data from more than 20 million patients, including decades of clinical records linked with genomic information.
The company uses artificial intelligence and machine learning to identify patient subtypes and applies causal inference techniques to determine the underlying drivers of disease. These insights are then integrated into its predictive chemistry platform to support the development of new therapeutics.
“The creation of this position and strategic appointment underscore the importance we place on human causal evidence as the foundation of drug discovery, and the opportunity we see for causal AI/ML tools to help solve the translational gap,” said Brian Alexander, M.D., M.P.H., CEO of Valo Health. “Dr. Anagnostopoulos brings an exceptionally rare skill set at the intersection of AI, statistics, and human biology. His expertise will be instrumental as we continue scaling this capability, enabling a new era of drug discovery that is anchored in human causal biology.”
Anagnostopoulos brings more than 20 years of experience across academia, consulting, technology and biopharma. He previously worked at QuantumBlack, AI by McKinsey, where he served as Tech Fellow Partner, Global Director of AI Innovation in Life Sciences, and co-founder of McKinsey’s Scientific AI service line.
Earlier in his career, he held senior roles at Improbable and served as an Associate Professor at Imperial College London.
“Drug discovery is struggling with a widening clinical translation gap, which consistently drives low clinical trial success rates, despite a growing number of drug candidates,” said Anagnostopoulos. “Addressing this causal gap requires integrating human causal biology insights as early as possible in drug discovery. Valo’s platform represents a truly differentiated way to do this, extracting causal mechanisms of disease from deep human data. I’m thrilled to join this talented team and work together to fully leverage causal AI to advance human health.”
Anagnostopoulos holds a Ph.D. in Statistics from Imperial College London and master’s degrees in machine learning from the University of Edinburgh and in theoretical computer science from the University of Athens. He completed his undergraduate studies in mathematics at Cambridge University and is a Chartered Statistician of the Royal Statistical Society. He also serves as an Honorary Associate Professor at Imperial College London.
